Advertisement

Topics

Motif Bio completes FDA submission for Iclaprim antibiotic

05:27 EDT 14 Jun 2018 | Proactive Investors

The AIM-listed bio-pharma company said Iclaprim had received Qualified Infectious Disease Product designation from the FDA together with Fast Track Designation

Original Article: Motif Bio completes FDA submission for Iclaprim antibiotic

NEXT ARTICLE

More From BioPortfolio on "Motif Bio completes FDA submission for Iclaprim antibiotic"

Advertisement
Quick Search
Advertisement
Advertisement

 

Relevant Topics

Infectious-diseases
Antiretroviral Therapy Clostridium Difficile Ebola HIV & AIDS Infectious Diseases Influenza Malaria Measles Sepsis Swine Flu Tropical Medicine Tuberculosis Infectious diseases are caused by pathogenic...

Drug Approvals
In order to become availible to pateints, drugs need to undergo a number of phases of clinical trials to test their efficacy and safty and to then be authorised by the drug approval organistion in each respective country. This is the FDA in the USA and N...